We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




CRISPR Variant Enables More Accurate Genome Editing

By LabMedica International staff writers
Posted on 13 Aug 2018
Print article
Image: An illustration showing the protein cas12a bound to a DNA helix (red and white) (Photo courtesy of T. Yamano and H. Nishimasu / James Rybarski).
Image: An illustration showing the protein cas12a bound to a DNA helix (red and white) (Photo courtesy of T. Yamano and H. Nishimasu / James Rybarski).
Results of a recent study suggested that inherent binding properties of the Cas12a enzyme make it a better choice for gene editing purposes than the currently used CRISPR/Cas9 combination.

CRISPR/Cas9 is regarded as the cutting edge of molecular biology technology. CRISPRs (clustered regularly interspaced short palindromic repeats) are segments of prokaryotic DNA containing short repetitions of base sequences. Each repetition is followed by short segments of "spacer DNA" from previous exposures to a bacterial virus or plasmid. Since 2013, the CRISPR/Cas9 system has been used in research for gene editing (adding, disrupting, or changing the sequence of specific genes) and gene regulation. By delivering the Cas9 enzyme and appropriate guide RNAs (sgRNAs) into a cell, the organism's genome can be cut at any desired location. The conventional CRISPR/Cas9 system is composed of two parts: the Cas9 enzyme, which cleaves the DNA molecule and specific RNA guides that shepherd the Cas9 protein to the target gene on a DNA strand.

Despite the widespread usage of CRISPR/Cas9, DNA cleavage at off-target sites that resemble the target sequence continues to be a pervasive problem that remains poorly understood mechanistically.

To solve the problem of off-target DNA cleavage, investigators at the University of Texas at Austin (USA) used quantitative kinetics to dissect the reaction steps of DNA targeting by Cas12a (also known as Cpf1 or Centromere and Promoter Factor 1). CRISPR/Cpf1 differs from CRISPR/Cas9 in a number of key ways. Cpf1 is much smaller than the Cas9 enzyme, which makes it easier to package inside a virus and therefore easier to deliver to muscle cells. It also recognizes a different sequence of DNA than Cas9 does, which provides greater flexibility in terms of use.

The investigators reported in the August 2, 2018, online edition of the journal Molecular Cell that Cas12a bound DNA tightly in two kinetically separable steps and discriminated strongly against mismatches along most of the DNA target sequence. In mechanistic terms, the investigators explained that Cas9, initially bound base pairs tightly together, but after the first seven or eight base pairs in the genomic target it paid less attention. This implied that Cas9 could overlook mismatches that could lead it to edit the wrong part of the genome. In contrast, Cas12a formed bonds that were relatively weak. Thus, it required a good match all along the target molecule to hold the complex together long enough to make an edit. Therefore it was much more likely to edit only the intended part of the genome.

"It makes the process of base-pair formation more reversible," said senior author Dr. Rick Russell, professor of molecular biosciences at University of Texas at Austin. "In other words, Cas12a does a better job of checking each base pair before moving on to the next one. After seven or eight letters, Cas9 stops checking, whereas Cas12a keeps on checking out to about 18 letters."

Related Links:
University of Texas at Austin

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb
New
Anti-HHV-6 IgM Assay
anti-HHV-6 IgM ELISA (semiquant.)

Print article

Channels

Molecular Diagnostics

view channel
Image: The study investigated D-dimer testing in patients who are at higher risk of pulmonary embolism (Photo courtesy of Adobe Stock)

D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism

Pulmonary embolism (PE) is a commonly suspected condition in emergency departments (EDs) and can be life-threatening if not diagnosed correctly. Achieving an accurate diagnosis is vital for providing effective... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.